(Q44603331)

4 December 2017

Linezolid for the treatment of complicated skin and skin structure infections in children (English)

1 reference

4 December 2017

1 reference

3

Sheldon L Kaplan

1 reference

4 December 2017

Ram Yogev

1

1 reference

4 December 2017

Stuart Adler

4

1 reference

4 December 2017

Maria Rayo Morfin

5

1 reference

4 December 2017

Amando Martin

6

1 reference

4 December 2017

Barbara Edge-Padbury

7

1 reference

4 December 2017

Sharon Naberhuis-Stehouwer

8

1 reference

4 December 2017

Lori E. Patterson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520143

16 March 2024

Jon B. Bruss

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520143

16 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14520143

16 March 2024

publication date

1 September 2003

1 reference

Pediatric Infectious Disease Journal

4 December 2017

1 reference

4 December 2017

22

1 reference

4 December 2017

S172-7

1 reference

4 December 2017

9 Suppl

1 reference

Optimal treatment of complicated skin and skin structure infections

4 December 2017

1

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Gram-positive resistance: challenge for the development of new antibiotics

16 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk

16 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Methicillin-resistant Staphylococcus aureus in the community: a hospital-based study.

16 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities

16 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Grou

16 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

16 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

16 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions

16 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

16 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

16 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program

16 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid

16 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children

16 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children

16 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Pharmacokinetics and tissue penetration of linezolid following multiple oral doses

16 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

16 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Linezolid resistance in a clinical isolate of Staphylococcus aureus

16 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium

16 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000088671.35064.7C

16 March 2024

Identifiers

1 reference

4 December 2017

1 reference